VITRAKVI

Peak

larotrectinib

NDAORALCAPSULEPriority Review
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
10

Mechanism of Action

Tropomyosin Receptor Kinases Inhibitors

Pharmacologic Class:

Kinase Inhibitor

Clinical Trials (5)

NCT05783323Phase 2Recruiting

Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

Started Feb 2024
13 enrolled
Differentiated Thyroid CancerPediatric CancerCancer+1 more
NCT05236257N/ACompleted

A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database

Started Mar 2022
93 enrolled
Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene FusionInfantile Fibrosarcoma
NCT05192642N/ACompleted

A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice

Started Dec 2021
368 enrolled
Solid Tumors Harboring NTRK Fusion
NCT04945330N/ARecruiting

NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes

Started Nov 2021
100 enrolled
Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion
NCT04814667N/ACompleted

A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib

Started Feb 2021
26 enrolled
Solid Tumor, AdultLocally Advanced Solid TumorMetastatic Cancer

Loss of Exclusivity

LOE Date
May 16, 2037
136 months away
Patent Expiry
May 16, 2037

Patent Records (5)

Patent #ExpiryTypeUse Code
9676783
Oct 21, 2029
U-2469
9447104
Oct 21, 2029
U-2470
8865698
Oct 21, 2029
U-2469
9127013
Oct 21, 2029
SubstanceProduct
10774085
Oct 21, 2029
U-2470